Company profile

Merck KGaA

MKKGY · OTC (ADR; primary listing Frankfurt/Xetra)

Share price · MKKGY

$31.67+4.03 (+14.58%) 3M

close as of 2026-08-18 · 24h delayed · vol 15K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Cladribine (MAVENCLAD®)
Approved
Adenosine deaminase-resistant purine analog · DNA synthesis machinery in lymphocytesSmall molecule
Multiple Sclerosis
Rebif (interferon beta 1a)
Approved
Interferon beta receptor (type I IFN signaling) · Type I interferon receptorBiologic — subtype unspecified
Multiple Sclerosis
Tepotinib
Approved
METSmall molecule
Non-Small Cell Lung Cancer
Nirogacestat
Phase 2
Gamma-secretase (presenilin complex)Small molecule
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.